Signaling to the p53 Tumor Suppressor through Pathways Activated by Genotoxic and Non-Genotoxic Stresses

Handbook of Cell Signaling, Second Edition

Volumn 3, Issue , 2009, Pages 2185-2204

  Anderson, Carl W ^a   Appella, Ettore ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882840365     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00264-3     Document Type: Chapter

References (216)

1. M Hollstein, G Moeckel, M Hergenhahn, B Spiegelhalder, M Keil, G Werle-Schneider, H Bartsch and J Brickmann (1998) On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 405 145-154.
2. T Soussi and KG Wiman (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12 303-312.
3. B Vogelstein, D Lane and AJ Levine (2000) Surfing the p53 network. Nature 408 307-310.
4. W-J Lu and JM Abrams (2006) Lessons from p53 in non-mammalian models. Cell Death Differ 13 909-912.
5. T Stiewe (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7 165-168.
6. J-C Bourdon, K Fernandes, F Murray-Zmijewski, G Liu, A Diot, DP Xirodimas, MK Saville and DP Lane (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19 2122-2137.
7. T Riley, E Sontag, P Chen and A Levine (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9 402-412.
8. E Meulmeester and AG Jochemsen (2008) p 53: a guide to apoptosis. Curr Cancer Drug Targets 8 87-97.
9. J Campisi and F d’Adda di Fagagna (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8 729-740.
10. ES Helton and X Chen (2007) p53 modulation of the DNA damage response. J Cell Biochem 100 883-896.
11. R Dawson, L Müller, A Dehner, C Klein, H Kessler and J Buchner (2003) The N-terminal domain of p53 is natively unfolded. J Mol Biol 332 1131-1141.
12. R Candau, DM Scolnick, P Darpino, CY Ying, TD Halazonetis and SL Berger (1997) Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15 807-816.
13. CD Allis, SL Berger, J Cote, S Dent, T Jenuwien, T Kouzarides, L Pillus, D Reinberg, Y Shi, R Shiekhattar, A Shilatifard, J Workman and Y Zhang (2007) New nomenclature for chromatin-modifying enzymes. Cell 131 633-636.
14. PH Kussie, S Gorina, V Marechal, B Elenbaas, J Moreau, AJ Levine and NP Pavletich (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 948-953.
15. Y Zhang and Y Xiong (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292 1910-1915.
16. KK Walker and AJ Levine (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 93 15,335-15,340.
17. JT Zilfou, WH Hoffman, M Sank, DL George and M Murphy (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol 21 3974-3985.
18. M Berger, N Stahl, G Del Sal and Y Haupt (2005) Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol Cell Biol 25 5380-5388.
19. F Toledo, KA Krummel, CJ Lee, C-W Liu, L-W Rodewald, M Tang and GM Wahl (2006) A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9 273-285.
20. P Di Lello, LMM Jenkins, TN Jones, BD Nguyen, T Hara, H Yamaguchi, JD Dikeakos, E Appella, P Legault and JG Omichinski (2006) Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell 22 731-740.
21. L Kaustov, G-S Yi, A Ayed, E Bochkareva, A Bochkarev and CH Arrowsmith (2006) p53 transcriptional activation domain: A molecular chameleon? Cell Cycle 5 489-494.
22. AC Joerger and AR Fersht (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77 557-582.
23. AC Joerger and AR Fersht (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26 2226-2242.
24. A Petitjean, E Mathe, S Kato, C Ishioka, SV Tavtigian, P Hainaut and M Olivier (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28 622-629.
25. WS El-Deiry, SE Kern, JA Pietenpol, KW Kinzler and B Vogelstein (1992) Definition of a consensus binding site for p53. Nat Genet 1 45-49.
26. DB Veprintsev and AR Fersht (2008) Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 36 1589-1598.
27. E Kim and W Deppert (2006) The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ 13 885-889.
28. KJ-L Riley and LJ Maher 3rd (2007) p 53 RNA interactions: new clues in an old mystery. RNA 13 1825-1833.
29. S Shetty, P Shetty, S Idell, T Velusamy, YP Bhandary and RS Shetty (2008) Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. J Biol Chem 283 19,570-19,580.
30. TR Hupp and DP Lane (1994) Allosteric activation of latent p53 tetramers. Curr Biol 4 865-875.
31. Y Liu, JP Lagowski, GE Vanderbeek and MF Kulesz-Martin (2004) Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain. Cancer Biol Ther 3 1102-1108.
32. K McKinney, M Mattia, V Gottifredi and C Prives (2004) p 53 linear diffusion along DNA requires its C terminus. Mol Cell 16 413-424.
33. A Tafvizi, F Huang, JS Leith, AR Fersht, LA Mirny and AM van Oijen (2008) Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys J 95 L01-L03.
34. H Tidow, R Melero, E Mylonas, SMV Freund, JG Grossmann, JM Carazo, DI Svergun, M Valle and AR Fersht (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci U S A 104 12,324-12,329.
35. E Appella and CW Anderson (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268 2764-2772.
36. AM Bode and Z Dong (2004) Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4 793-805.
37. JP Kruse and W Gu (2008) SnapShot: p53 posttranslational modifications. Cell 133 930-e931.
38. GP Shouse, X Cai and X Liu (2008) Serine 15 phosphorylation of p53 directs its interaction with B56γ and the tumor suppressor activity of B56γ-specific protein phosphatase 2A. Mol Cell Biol 28 448-456.
39. AW Braithwaite, G Del Sal and X Lu (2006) Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ 13 984-993.
40. D Bech-Otschir, R Kraft, X Huang, P Henklein, B Kapelari, C Pollmann and W Dubiel (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20 1630-1639.
41. WH Yang, JE Kim, HW Nam, JW Ju, HS Kim, YS Kim and JW Cho (2006) Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 8 1074-1083.
42. Q Liu, S Kaneko, L Yang, RI Feldman, SV Nicosia, J Chen and JQ Cheng (2004) Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279 52,175-52,182.
43. Y Tang, J Luo, W Zhang and W Gu (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24 827-839.
44. SM Sykes, HS Mellert, MA Holbert, K Li, R Marmorstein, WS Lane and SB McMahon (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24 841-851.
45. Y Tang, W Zhao, Y Chen, Y Zhao and W Gu (2008) Acetylation is indispensable for p53 activation. Cell 133 612-626.
46. IR Watson and MS Irwin (2006) Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8 655-666.
47. CL Brooks and W Gu (2006) p 53 Ubiquitination: Mdm2 and beyond. Mol Cell 21 307-315.
48. MJF Waterman, ES Stavridi, JLF Waterman and TD Halazonetis (1998) ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet 19 175-178.
49. A Olsson, C Manzl, A Strasser and A Villunger (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14 1561-1575.
50. F Toledo, CJ Lee, KA Krummel, L-W Rodewald, C-W Liu and GM Wahl (2007) Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol 27 1425-1432.
51. S Saito Jr, H Yamaguchi, Y Higashimoto, C Chao, Y Xu, AJ Fornace, E Appella and CW Anderson (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278 37,536-37,544.
52. N Dumaz, DM Milne and DW Meek (1999) Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett 463 312-316.
53. JK Kurash, H Lei, Q Shen, WL Marston, BW Granda, H Fan, D Wall, E Li and F Gaudet (2008) Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 29 392-400.
54. C Chao, D Herr, J Chun and Y Xu (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25 2615-2622.
55. L Le Cam, LK Linares, C Paul, E Julien, M Lacroix, E Hatchi, R Triboulet, G Bossis, A Shmueli, MS Rodriguez, O Coux and C Sardet (2006) E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell 127 775-788.
56. AL Talis, JM Huibregtse and PM Howley (1998) The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 273 6439-6445.
57. E Querido, P Blanchette, Q Yan, T Kamura, M Morrison, D Boivin, WG Kaelin, RC Conaway, JW Conaway and PE Branton (2001) Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15 3104-3117.
58. Y Yang, C-CH Li and AM Weissman (2004) Regulating the p53 system through ubiquitination. Oncogene 23 2096-2106.
59. X Wu, JH Bayle, D Olson and AJ Levine (1993) The p53-mdm-2 autoregulatory feedback loop. Genes & Development 7 1126-1132.
60. S-Y Shieh, M Ikeda, Y Taya and C Prives (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 325-334.
61. NH Chehab, A Malikzay, ES Stavridi and TD Halazonetis (1999) Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A 96 13,777-13,782.
62. AL Craig, L Burch, B Vojtesek, J Mikutowska, A Thompson and TR Hupp (1999) Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342 133-141.
63. K Sakaguchi, S Saito, Y Higashimoto, S Roy, CW Anderson and E Appella (2000) Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275 9278-9283.
64. T Unger, T Juven-Gershon, E Moallem, M Berger, R Vogt Sionov, G Lozano, M Oren and Y Haupt (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18 1805-1814.
65. HJ Lee, D Srinivasan, D Coomber, DP Lane and CS Verma (2007) Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle 6 2604-2611.
66. C Chao, S Saito, CW Anderson, E Appella and Y Xu (2000) Phosphorylation of murine p53 at Ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci U S A 97 11,936-11,941.
67. PF Lambert, F Kashanchi, MF Radonovich, R Shiekhattar and JN Brady (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273 33,048-33,053.
68. S Polley, S Guha, NS Roy, S Kar, K Sakaguchi, Y Chuman, V Swaminathan, T Kundu and S Roy (2008) Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J Mol Biol 376 8-12.
69. R Kulikov, M Winter and C Blattner (2006) Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem 281 28,575-28,583.
70. GW Yu, S Rudiger, D Veprintsev, S Freund, MR Fernandez-Fernandez and AR Fersht (2006) The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A 103 1227-1232.
71. DW Meek and U Knippschild (2003) Posttranslational modification of MDM2. Mol Cancer Res 1 1017-1026.
72. KA Boehme, R Kulikov and C Blattner (2008) p 53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A 105 7785-7790.
73. K Itahana, H Mao, A Jin, Y Itahana, HV Clegg, MS Lindström, KP Bhat, VL Godfrey, GI Evan and Y Zhang (2007) Targeted inactivation of Mdm2 RING Finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12 355-366.
74. F Toledo and GM Wahl (2007) MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39 1476-1482.
75. J Parant, A Chavez-Reyes, NA Little, W Yan, V Reinke, AG Jochemsen and G Lozano (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29 92-95.
76. LK Linares, R Kiernan, R Triboulet, C Chable-Bessia, D Latreille, O Cuvier, M Lacroix, L Le Cam, O Coux and M Benkirane (2007) Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 9 331-338.
77. J Tang, L-K Qu, J Zhang, W Wang, JS Michaelson, YY Degenhardt, WS El-Deiry and X Yang (2006) Critical role for Daxx in regulating Mdm2. Nat Cell Biol 8 855-862.
78. D Dornan, H Shimizu, A Mah, T Dudhela, M Eby, K O’Rourke, S Seshagiri and VM Dixit (2006) ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage. Science 313 1122-1126.
79. S Duan, Z Yao, D Hou, Z Wu, W-G Zhu and M Wu (2007) Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53. EMBO J 26 3062-3074.
80. D Chen, CL Brooks and W Gu (2006) ARF-BP1 as a potential therapeutic target. Br J Cancer 94 1555-1558.
81. X Zhao, JI-T Heng, D Guardavaccaro, R Jiang, M Pagano, F Guillemot, A Iavarone and A Lasorella (2008) The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat Cell Biol 10 643-653.
82. T Thompson, C Tovar, H Yang, D Carvajal, BT Vu, Q Xu, GM Wahl, DC Heimbrook and LT Vassilev (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279 53,015-53,022.
83. MD Kaeser and RD Iggo (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A 99 95-100.
84. NG Iyer, S-F Chin, H Ozdag, Y Daigo, D-E Hu, M Cariati, K Brindle, S Aparicio and C Caldas (2004) p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A 101 7386-7391.
85. K Sakaguchi, JE Herrera, S Saito, T Miki, M Bustin, A Vassilev, CW Anderson and E Appella (1998) DNA damage activates p53 through a phosphorylation–acetylation cascade. Genes Dev 12 2831-2841.
86. C Chao, Z Wu, SJ Mazur, H Borges, M Rossi, T Lin, JYJ Wang, CW Anderson, E Appella and Y Xu (2006) Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 26 6859-6869.
87. M Cordenonsi, M Montagner, M Adorno, L Zacchigna, G Martello, A Mamidi, S Soligo, S Dupont and S Piccolo (2007) Integration of TGF-β and Ras/MAPK signaling through p53 phosphorylation. Science 315 840-843.
88. AG Li, LG Piluso, X Cai, G Wei, WR Sellers and X Liu (2006) Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 23 575-587.
89. MD Kaeser and RD Iggo (2004) Promoter-specific p53-dependent histone acetylation following DNA damage. Oncogene 23 4007-4013.
90. P Wang, J Yu and L Zhang (2007) The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci U S A 104 4054-4059.
91. NA Barlev, L Liu, NH Chehab, K Mansfield, KG Harris, TD Halazonetis and SL Berger (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8 1243-1254.
92. J Luo, AY Nikolaev, S Imai, D Chen, F Su, A Shiloh, L Guarente and W Gu (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107 137-148.
93. H Vaziri, SK Dessain, EN Eaton, SI Imai, RA Frye, TK Pandita, L Guarente and RA Weinberg (2001) hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107 149-159.
94. E Langley, M Pearson, M Faretta, U-M Bauer, RA Frye, S Minucci, PG Pelicci and T Kouzarides (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21 2383-2396.
95. M Murphy, J Ahn, KK Walker, WH Hoffman, RM Evans, AJ Levine and DL George (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13 2490-2501.
96. V Basile, R Mantovani and C Imbriano (2006) DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines. J Biol Chem 281 2347-2357.
97. GS Ivanov 3rd, T Ivanova, J Kurash, A Ivanov, S Chuikov, F Gizatullin, EM Herrera-Medina, F Rauscher, D Reinberg and NA Barlev (2007) Methylation–acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol 27 6756-6769.
98. J Huang, L Perez-Burgos, BJ Placek, R Sengupta, M Richter, JA Dorsey, S Kubicek, S Opravil, T Jenuwein and SL Berger (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature 444 629-632.
99. J Huang, R Sengupta, AB Espejo, MG Lee, JA Dorsey, M Richter, S Opravil, R Shiekhattar, MT Bedford, T Jenuwein and SL Berger (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449 105-108.
100. DJ Derbyshire, BP Basu, LC Serpell, WS Joo, T Date, K Iwabuchi and AJ Doherty (2002) Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 21 3863-3872.
101. X Shi, I Kachirskaia, H Yamaguchi, LE West, H Wen, EW Wang, S Dutta, E Appella and O Gozani (2007) Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell 27 636-646.
102. W An, J Kim and RG Roeder (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117 735-748.
103. P Li, H Yao, Z Zhang, M Li, Y Luo, PR Thompson, DS Gilmour and Y Wang (2008) Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 28 4745-4758.
104. DV Bulavin Jr, S Saito, MC Hollander, K Sakaguchi, CW Anderson, E Appella and AJ Fornace (1999) Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18 6845-6854.
105. MA Calzado, F Renner, A Roscic and ML Schmitz (2007) HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle 6 139-143.
106. N Taira, K Nihira, T Yamaguchi, Y Miki and K Yoshida (2007) DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25 725-738.
107. K Yoshida, H Liu and Y Miki (2006) Protein Kinase C d regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 281 5734-5740.
108. J-H Lee, H-S Kim, S-J Lee and K-T Kim (2007) Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death. J Cell Sci 120 2259-2271.
109. K Oda, H Arakawa, T Tanaka, K Matsuda, C Tanikawa, T Mori, H Nishimori, K Tamai, T Tokino, Y Nakamura and Y Taya (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 849-862.
110. M Winter, D Sombroek, I Dauth, J Moehlenbrink, K Scheuermann, J Crone and TG Hofmann (2008) Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10 812-824.
111. JM Espinosa (2008) Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27 4013-4023.
112. Das S, Boswell SA, Aaronson SA, Lee SW. p53 promoter selection: Choosing between life and death. Cell Cycle 2007;7.
113. AL Fachin, SS Mello, P Sandrin-Garcia, CM Junta, EA Donadi, GAS Passos and ET Sakamoto-Hojo (2007) Gene expression profiles in human lymphocytes irradiated in vitro with low doses of gamma rays. Radiat Res 168 650-665.
114. SA Amundson, RA Lee, CA Koch-Paiz, ML Bittner, P Meltzer, JM Trent and AJ Fornace Jr (2003) Differential responses of stress genes to low dose-rate gamma irradiation. Mol Cancer Res 1 445-452.
115. Y Shiloh (2006) The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 31 402-410.
116. S Saito, AA Goodarzi, Y Higashimoto, Y Noda, SP Lees-Miller, E Appella and CW Anderson (2002) ATM mediates phosphorylation at multiple p53 sites, including Ser46, in response to ionizing radiation. J Biol Chem 277 12,491-12,494.
117. CJ Bakkenist and MB Kastan (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 499-506.
118. A Rupnik, M Grenon and N Lowndes (2008) The MRN complex. Curr Biol 18 R455-R457.
119. J-H Lee and TT Paull (2007) Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26 7741-7748.
120. I Ward and J Chen (2004) Early events in the DNA damage response. Curr Top Dev Biol 63 1-35.
121. S Matsuoka 3rd, BA Ballif, A Smogorzewska, ER McDonald, KE Hurov, J Luo, CE Bakalarski, Z Zhao, N Solimini, Y Lerenthal, Y Shiloh, SP Gygi and SJ Elledge (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316 1160-1166.
122. M Pellegrini, A Celeste, S Difilippantonio, R Guo, W Wang, L Feigenbaum and A Nussenzweig (2006) Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 443 222-225.
123. SV Kozlov, ME Graham, C Peng, P Chen, PJ Robinson and MF Lavin (2006) Involvement of novel autophosphorylation sites in ATM activation. EMBO J 25 3504-3514.
124. Y Sun, Y Xu and K Roy (2007) DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 27 8502-8509.
125. MB Kastan Jr, Q Zhan, WS El-Deiry, F Carrier, T Jacks, WV Walsh, BS Plunkett, B Vogelstein and AJ Fornace (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 587-597.
126. KA Cimprich and D Cortez (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9 616-627.
127. Y Zhang, W-Y Ma, A Kaji, AM Bode and Z Dong (2002) Requirement of ATM in UVA-induced signaling and apoptosis. J Biol Chem 277 3124-3131.
128. M Ljungman (2007) The transcription stress response. Cell Cycle 6 2252-2257.
129. T Stiff, SA Walker, K Cerosaletti, AA Goodarzi, E Petermann, P Concannon, M O’Driscoll and PA Jeggo (2006) ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J 25 5775-5782.
130. M Gatei, K Sloper, C Sörensen, R Syljuäsen, J Falck, K Hobson, K Savage, J Lukas, B-B Zhou, J Bartek and KK Khanna (2003) Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278 14,806-14,811.
131. PJ Hurley and F Bunz (2007) ATM and ATR: components of an integrated circuit. Cell Cycle 6 414-417.
132. A Kumagai, J Lee, HY Yoo and WG Dunphy (2006) TopBP1 activates the ATR-ATRIP complex. Cell 124 943-955.
133. DA Mordes, GG Glick, R Zhao and D Cortez (2008) TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev 22 1478-1489.
134. K Ünsal-Kaçmaz, PD Chastain, P-P Qu, P Minoo, M Cordeiro-Stone, A Sancar and WK Kaufmann (2007) The human Tim/Tipin complex coordinates an Intra-S checkpoint response to UV that slows replication fork displacement. Mol Cell Biol 27 3131-3142.
135. K Webley, JA Bond, CJ Jones, JP Blaydes, A Craig, T Hupp and D Wynford-Thomas (2000) Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 20 2803-2808.
136. F d’Adda di Fagagna (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 8 512-522.
137. CJ Sherr (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2 731-737.
138. CJ Sherr (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6 663-673.
139. E de Stanchina, ME McCurrach, F Zindy, SY Shieh, G Ferbeyre, AV Samuelson, C Prives, MF Roussel, CJ Sherr and SW Lowe (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12 2434-2442.
140. O Vafa, M Wade, S Kern, M Beeche, TK Pandita, GM Hampton and GM Wahl (2002) c-myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function. A mechanism for oncogene-induced genetic instability. Mol Cell 9 1031-1044.
141. G Ferbeyre, E de Stanchina, AW Lin, E Querido, ME McCurrach, GJ Hannon and SW Lowe (2002) Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 22 3497-3508.
142. DV Bulavin, ON Demidov, S Saito, P Kauraniemi, C Phillips, SA Amundson, C Ambrosino, G Sauter, AR Nebreda, CW Anderson, A Kallioniemi, AJ Fornace Jr and E Appella (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31 210-215.
143. FA Mallette and G Ferbeyre (2007) The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6 1831-1836.
144. R Di Micco, M Fumagalli, A Cicalese, S Piccinin, P Gasparini, C Luise, C Schurra, M Garre, PG Nuciforo, A Bensimon, R Maestro, PG Pelicci and F d’Adda di Fagagna (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444 638-642.
145. M Ljungman, HM O’Hagan and MT Paulsen (2001) Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20 5964-5971.
146. AJ Levine, Z Feng, TW Mak, H You and S Jin (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20 267-275.
147. F Zhangé, RB Hamanaka and E Bobrovnikova-Marjon (2006) Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest. J. Biol Chem 281 30,036-30,045.
148. L Zhao and SL Ackerman (2006) Endoplasmic reticulum stress in health and disease. Curr Opin Cell Biol 18 444-452.
149. J Wu and RJ Kaufman (2006) From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ 13 374-384.
150. L Qu, S Huang, D Baltzis, A-M Rivas-Estilla, O Pluquet, M Hatzoglou, C Koumenis, Y Taya, A Yoshimura and AE Koromilas (2004) Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev 18 261-277.
151. H Katayama, K Sasai, H Kawai, Z-M Yuan, J Bondaruk, F Suzuki, S Fujii, RB Arlinghaus, BA Czerniak and S Sen (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36 55-62.
152. S Yamasaki, N Yagishita, T Sasaki, M Nakazawa, Y Kato, T Yamadera, E Bae, S Toriyama, R Ikeda, L Zhang, K Fujitani, E Yoo, K Tsuchimochi, T Ohta, N Araya, H Fujita, S Aratani, K Eguchi, S Komiya, I Maruyama, N Higashi, M Sato, H Senoo, T Ochi, S Yokoyama, T Amano, J Kim, S Gay, A Fukamizu, K Nishioka, K Tanaka and T Nakajima (2006) Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase “Synoviolin.”. EMBO J 26 113-122.
153. EM Hammond, MR Kaufmann and AJ Giaccia (2007) Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol 19 680-684.
154. EM Hammond and AJ Giaccia (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331 718-725.
155. EM Hammond, MJ Dorie and AJ Giaccia (2003) ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem 278 12,207-12,213.
156. LE Huang, RS Bindra, PM Glazer and AL Harris (2007) Hypoxia-induced genetic instability: a calculated mechanism underlying tumor progression. J Mol Med 85 139-148.
157. T van den Beucken, M Koritzinsky and BG Wouters (2006) Translational control of gene expression during hypoxia. Cancer Biol Ther 5 749-755.
158. Q Ke and M Costa (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70 1469-1480.
159. PH Maxwell, MS Wiesener, G-W Chang, SC Clifford, EC Vaux, ME Cockman, CC Wykoff, CW Pugh, ER Maher and PJ Ratcliffe (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 271-275.
160. R Alarcón, C Koumenis, RK Geyer, CG Maki and AJ Giaccia (1999) Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 59 6046-6051.
161. EM Hammond, NC Denko, MJ Dorie, RT Abraham and AJ Giaccia (2002) Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 22 1834-1843.
162. C Koumenis, R Alarcon, E Hammond, P Sutphin, W Hoffman, M Murphy, J Derr, Y Taya, SW Lowe, M Kastan and A Giaccia (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21 1297-1310.
163. LO Hansson, A Friedler, S Freund, S Rüdiger and AR Fersht (2002) Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A 99 10,305-10,309.
164. WG An, M Kanekal, MC Simon, E Maltepe, MV Blagosklonny and LM Neckers (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 405-408.
165. EM Hammond, DJ Mandell, A Salim, AJ Krieg, TM Johnson, HA Shirazi, LD Attardi and AJ Giaccia (2006) Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol 26 3492-3504.
166. N Hay and N Sonenberg (2004) Upstream and downstream of mTOR. Genes Dev 18 1926-1945.
167. K Imamura, T Ogura, A Kishimoto, M Kaminishi and H Esumi (2001) Cell cycle regulation via p53 phosphorylation by a 5’-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287 562-567.
168. RG Jones, DR Plas, S Kubek, M Buzzai, J Mu, Y Xu, MJ Birnbaum and CB Thompson (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18 283-293.
169. R Okoshi, T Ozaki, H Yamamoto, K Ando, N Koida, S Ono, T Koda, T Kamijo, A Nakagawara and H Kizaki (2008) Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283 3979-3987.
170. Z Feng, H Zhang, AJ Levine and S Jin (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A 102 8204-8209.
171. P Karuman, O Gozani, RD Odze, XC Zhou, H Zhu, R Shaw, TP Brien, CD Bozzuto, D Ooi, LC Cantley and J Yuan (2001) The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 7 1307-1319.
172. K Kawauchi, K Araki, K Tobiume and N Tanaka (2008) p 53 regulates glucose metabolism through an IKK-NFκB pathway and inhibits cell transformation. Nat Cell Biol 10 611-618.
173. S Matoba, J-G Kang, WD Patino, A Wragg, M Boehm, O Gavrilova, PJ Hurley, F Bunz and PM Hwang (2006) p53 regulates mitochondrial respiration. Science 312 1650-1653.
174. SP Linke, KC Clarkin, A Di Leonardo, A Tsou and GM Wahl (1996) A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10 934-947.
175. G Seidita, D Polizzi, G Costanzo, S Costa and A Di Leonardo (2000) Differential gene expression in p53-mediated G1 arrest of human fibroblasts after gamma-irradiation or N-phosphoacetyl-L-aspartate treatment. Carcinogenesis 21 2203-2210.
176. K Hastak, RK Paul, MK Agarwal, VS Thakur, ARMR Amin, S Agrawal, RM Sramkoski, JW Jacobberger, MW Jackson, GR Stark and ML Agarwal (2008) DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci U S A 105 6314-6319.
177. JL Bronder and RG Moran (2003) A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 278 48,861-48,871.
178. X-X Sun, M-S Dai and H Lu (2008) Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 283 12,387-12,392.
179. F-M Boisvert, S van Koningsbruggen, J Navascués and AI Lamond (2007) The multifunctional nucleolus. Nat Rev Mol Cell Biol 8 574-585.
180. CP Rubbi and J Milner (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 22 6068-6077.
181. MO Olson (2004) Sensing cellular stress: another new function for the nucleolus? Sci STKE pe10.
182. S Kurki, K Peltonen and M Laiho (2004) Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle 3 976-979.
183. MAE Lohrum, RL Ludwig, MHG Kubbutat, M Hanlon and KH Vousden (2003) Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3 577-587.
184. Y Zhang, GW Wolf, K Bhat, A Jin, T Allio, WA Burkhart and Y Xiong (2003) Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23 8902-8912.
185. KP Bhat, K Itahana, A Jin and Y Zhang (2004) Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J 23 2402-2412.
186. M-S Dai and H Lu (2004) Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279 44,475-44,482.
187. M-S Dai, SX Zeng, Y Jin, X-X Sun, L David and H Lu (2004) Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24 7654-7668.
188. A Jin, K Itahana, K O’Keefe and Y Zhang (2004) Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24 7669-7680.
189. A Saxena, CJ Rorie, D Dimitrova, Y Daniely and JA Borowiec (2006) Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene 25 7274-7288.
190. M-S Dai, X-X Sun and H Lu (2008) Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 28 4365-4376.
191. C Korgaonkar, J Hagen, V Tompkins, AA Frazier, C Allamargot, FW Quelle and DE Quelle (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25 1258-1271.
192. SH Khan and GM Wahl (1998) p 53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 58 396-401.
193. AA Sablina, PM Chumakov, AJ Levine and BP Kopnin (2001) p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene 20 899-909.
194. ZA Stewart, LJ Tang and JA Pietenpol (2001) Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Oncogene 20 113-124.
195. G Damia, L Filiberti, F Vikhanskaya, L Carrassa, Y Taya, M D’incalci and M Broggini (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3 10-16.
196. L Li, M Ljungman and JE Dixon (2000) The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53. J Biol Chem 275 2410-2414.
197. MT Paulsen, AM Starks, FA Derheimer, S Hanasoge, L Li, JE Dixon and M Ljungman (2006) The p53-targeting human phosphatase hCdc14A interacts with the Cdk1/cyclin B complex and is differentially expressed in human cancers. Mol Cancer 5 25.
198. X Long, G Wu, ST Gaa and TB Rogers (2002) Inhibition of protein phosphatase-1 is linked to phosphorylation of p53 and apoptosis. Apoptosis 7 31-39.
199. M Haneda, E Kojima, A Nishikimi, T Hasegawa, I Nakashima and K Isobe (2004) Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA-damaging stress-induced phospho-serine 15 of p53. FEBS Lett 567 171-174.
200. DW-C Li, J-P Liu, PC Schmid, R Schlosser, H Feng, W-B Liu, Q Yan, L Gong, S-M Sun, M Deng and Y Liu (2006) Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 25 3006-3022.
201. X Tang, Z-G Hui, X-L Cui, R Garg, MB Kastan and B Xu (2008) A novel ATM-dependent pathway regulates protein phosphatase 1 in response to DNA damage. Mol Cell Biol 28 2559-2566.
202. S-J Lee, C-J Lim, J-K Min, J-K Lee, Y-M Kim, J-Y Lee, M-H Won and Y-G Kwon (2007) Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2. Cell Death Differ 14 1106-1116.
203. H-H Li, X Cai, GP Shouse, LG Piluso and X Liu (2007) A specific PP2A regulatory subunit, B56γ, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 26 402-411.
204. KM Dohoney, C Guillerm, C Whiteford, C Elbi, PF Lambert, GL Hager and JN Brady (2004) Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene 23 49-57.
205. M Kong, CJ Fox, J Mu, L Solt, A Xu, RM Cinalli, MJ Birnbaum, T Lindsten and CB Thompson (2004) The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science 306 695-698.
206. T Lammers and S Lavi (2007) Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. Crit Rev Biochem Mol Biol 42 437-461.
207. M Fiscella, H Zhang, S Fan, K Sakaguchi, S Shen, WE Mercer, GF Vande Woude, PM O’Connor and E Appella (1997) Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94 6048-6053.
208. M Takekawa, M Adachi, A Nakahata, I Nakayama, F Itoh, H Tsukuda, Y Taya and K Imai (2000) p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19 6517-6526.
209. DV Bulavin Jr, C Phillips, B Nannenga, O Timofeev, LA Donehower, CW Anderson, E Appella and AJ Fornace (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19Arf pathway. Nat Genet 36 343-350.
210. S Shreeram, ON Demidov, WK Hee, H Yamaguchi, N Onishi, C Kek, ON Timofeev, C Dudgeon, AJ Fornace, CW Anderson, Y Minami, E Appella and DV Bulavin (2006) Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 23 757-764.
211. S Shreeram Jr, WK Hee, ON Demidov, C Kek, H Yamaguchi, AJ Fornace, CW Anderson, E Appella and DV Bulavin (2006) Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 203 2793-2799.
212. H Yamaguchi, SR Durell, DK Chatterjee, CW Anderson and E Appella (2007) The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry 46 12,594-12,603.
213. X Lu, B Nannenga and LA Donehower (2005) PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19 1162-1174.
214. X Lu, O Ma, T-A Nguyen, SN Jones, M Oren and LA Donehower (2007) The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12 342-354.
215. P Ofek, D Ben-Meir, Z Kariv-Inbal, M Oren and S Lavi (2003) Cell cycle regulation and p53 activation by protein phosphatase 2Cα. J Biol Chem 278 14,299-14,305.
216. TM Johnson and LD Attardi (2006) Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice. Cell Death Differ 13 902-908.